224 related articles for article (PubMed ID: 34213682)
1. Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance.
Uddin R; Darwish NHE; Mousa SA
Curr Treat Options Oncol; 2021 Jul; 22(9):76. PubMed ID: 34213682
[TBL] [Abstract][Full Text] [Related]
2. Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.
Sami SA; Darwish NHE; Barile ANM; Mousa SA
Curr Treat Options Oncol; 2020 Jan; 21(1):3. PubMed ID: 31933183
[TBL] [Abstract][Full Text] [Related]
3. Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities.
Marchand T; Pinho S
Front Immunol; 2021; 12():775128. PubMed ID: 34721441
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia: 2019 update on risk-stratification and management.
Estey EH
Am J Hematol; 2018 Oct; 93(10):1267-1291. PubMed ID: 30328165
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia.
Morsink LM; Walter RB; Ossenkoppele GJ
Blood Rev; 2019 Mar; 34():26-33. PubMed ID: 30401586
[TBL] [Abstract][Full Text] [Related]
6. [Acute myeloid Leukemia].
Braess J
Dtsch Med Wochenschr; 2016 Nov; 141(24):1748-1751. PubMed ID: 27835920
[TBL] [Abstract][Full Text] [Related]
7. Updates on targeted therapies for acute myeloid leukaemia.
Kayser S; Levis MJ
Br J Haematol; 2022 Jan; 196(2):316-328. PubMed ID: 34350585
[TBL] [Abstract][Full Text] [Related]
8. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
9. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.
Zeng Z; Liu W; Tsao T; Qiu Y; Zhao Y; Samudio I; Sarbassov DD; Kornblau SM; Baggerly KA; Kantarjian HM; Konopleva M; Andreeff M
Haematologica; 2017 Sep; 102(9):1537-1548. PubMed ID: 28659338
[TBL] [Abstract][Full Text] [Related]
10. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
Megías-Vericat JE; Martínez-Cuadrón D; Solana-Altabella A; Montesinos P
Expert Rev Hematol; 2020 Oct; 13(10):1057-1065. PubMed ID: 32869672
[TBL] [Abstract][Full Text] [Related]
11. Treatment options for older unfit patients with acute myeloid leukemia.
Tang H; Jia S; Bi L; Jia W; Gao G
Future Oncol; 2021 Mar; 17(7):837-851. PubMed ID: 33522289
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases.
Campregher PV; Mattos VRP; Salvino MA; Santos FPS; Hamerschlak N
Einstein (Sao Paulo); 2017; 15(3):355-358. PubMed ID: 28746590
[TBL] [Abstract][Full Text] [Related]
13. New agents for the treatment of acute myeloid leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
[TBL] [Abstract][Full Text] [Related]
14. Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia.
Wang J; Tomlinson B; Lazarus HM
Curr Treat Options Oncol; 2023 Jul; 24(7):770-801. PubMed ID: 37195589
[TBL] [Abstract][Full Text] [Related]
15. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Relapsed Acute Myeloid Leukemia.
Thol F; Ganser A
Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
[TBL] [Abstract][Full Text] [Related]
17. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
Pelosi E; Castelli G; Testa U
Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257
[TBL] [Abstract][Full Text] [Related]
18.
Naqvi K; Ravandi F
Leuk Lymphoma; 2019 Aug; 60(8):1866-1876. PubMed ID: 30997851
[TBL] [Abstract][Full Text] [Related]
19. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia transformed to a targetable disease.
Saleh K; Khalifeh-Saleh N; Kourie HR
Future Oncol; 2020 May; 16(14):961-972. PubMed ID: 32297538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
